Lung Cancer Therapeutics Market Size, Share, Growth Analysis, By Therapy(Targeted Therapy (Bevacizumab, Dabrafenib/Trametinib, Erlotinib Hydrochloride, Osimertinib), By Cancer Type(Non-small cell lung cancer (NSCLC), and Small cell lung cancer (SCLC)), By Distribution Channel(Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others), By Region - Industry Forecast 2024-2031

The top market participants have a wide geographic reach and a wide range of products to meet a variety of consumer wants. Industry players are spending a lot of money on R&D in order to introduce new Treatment and increase their profitability in this potential market

Lung Cancer Therapeutics Market Top Player’s Company Profiles

• Genentech (F. Hoffmann-La Roche Ltd) 
• Eli Lilly and Company 
• Celgene Corporation  
• AstraZeneca 
• Pfizer Inc. 
• Sanofi 
• Novartis AG 
• Astellas Pharma Inc. 
• Bristol Myers Squibb 
• Boehringer Ingelheim Pharmaceuticals, Inc. 
• Millennium Pharmaceuticals, Inc. (Takeda) 
• Merck Sharp & Dohme Corp. 
• Eisai Co., Ltd. 
• Johnson & Johnson 
• Bayer AG 
• GlaxoSmithKline plc 
• Amgen Inc. 
• Spectrum Pharmaceuticals, Inc. 

Lung Cancer Therapeutics Market Recent Development

• In March 2022, AstraZeneca, PATH, and Qure.ai have teamed up to improve lung health in low- and middle-income countries. These three companies will collaborate to create a framework for using cutting-edge artificial intelligence technologies to detect lung cancer in patients undergoing chest screening for tuberculosis.
• In March 2022, Duke University has joined Known Medicine, a rapidly expanding biotechnology company that specializes in finding potent anticancer medications, to determine the efficacy of the drugs for patients with lung cancer. Through this agreement, Known Medicine will be able to evaluate and improve their ODINTM platform. Both parties want to assess the platform's ability to predict clinical outcomes accurately in about 75 patients.